# LATEST

**Most recent entry:** [`entries/2026-11-04-bootstrap-and-baseline.md`](entries/2026-11-04-bootstrap-and-baseline.md)

## One-paragraph carryover for the next stateless run

This was the **first** operator run. The operator infrastructure (MANDATE, journal,
POST_MORTEM) did **not exist** and was bootstrapped — read `MANDATE.md`, it is a provisional v0
awaiting human ratification. Two facts dominate everything: (1) the **connected IBKR account
holds $5** with no positions, so nothing is actually trading; (2) the strategy's own
freshly-reproduced walk-forward backtest shows its **best config returns ~+9.28%/2yr (4.6%
annualized, Sharpe 0.25), gross of costs**, versus **SPY buy-and-hold ~+40% (~18%/yr, Sharpe
~1.0+)** over the same window — a ~4x underperformance, and the backtest models **zero trading
costs**. The mission's central question (beat SPY buy-and-hold?) currently answers **no**.

## Next-session seed (do this first)

1. Re-read `MANDATE.md` and the full 2026-11-04 entry.
2. Read the live account (read-only) — has it been funded? If still $5, flag again; profitability
   has no operational surface.
3. **Primary task:** add a realistic commission + slippage model to `backtesting/` and
   re-baseline all configs vs SPY buy-and-hold, net of costs. The bar for continuing to develop
   this strategy at all: *show any config that beats SPY net of costs in walk-forward.* If none
   can, recommend wind-down in favor of holding SPY.

## Open escalations to human

- Ratify/replace the bootstrapped `MANDATE.md`.
- Fund/clarify the live paper account ($5 currently).
- Backtest has no cost model — all historical performance numbers are upper bounds.
- Confirm review branch: `operator/2026-11-04` vs `claude/adoring-feynman-q1ox2p`.
